Kang‐Yi Su

Pretreatment Epidermal Growth Factor Receptor ( <i>EGFR</i> ) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer

Kang‐Yi Su, Hsuan‐Yu Chen, Ker-Chau Li et al. · Journal of Clinical Oncology · 2012 · 494 citations · Full text

Medicine, Oncology, Pharmacology +15

Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression

Yi‐Ju Chen, Theodoros I. Roumeliotis, Ya‐Hsuan Chang et al. · Cell · 2020 · 384 citations · Full text

Medicine, Molecular Biology, Oncology +17

Slug Confers Resistance to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Tzu‐Hua Chang, Meng-Feng Tsai, Kang‐Yi Su et al. · American Journal of Respiratory and Critical Care Medicine · 2010 · 165 citations

Medicine, Cancer Biology, Oncology +17

Enterovirus-Induced miR-141 Contributes to Shutoff of Host Protein Translation by Targeting the Translation Initiation Factor eIF4E

Bing‐Ching Ho, Sung‐Liang Yu, Jeremy J.W. Chen et al. · Cell Host & Microbe · 2011 · 161 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +16

Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study

Chia‐Chi Lin, Jin‐Yuan Shih, Chong‐Jen Yu et al. · The Lancet Respiratory Medicine · 2017 · 144 citations

Medicine, Genetics, Oncology +16